Stock Price
568.58
Daily Change
-7.21 -1.25%
Monthly
-2.06%
Yearly
86.21%
Q2 Forecast
557.15

United Therapeutics reported $200M in Debt for its fiscal quarter ending in March of 2025.





Debt Change Date
Amarin USD 0 0 Mar/2025
Ardelyx USD 207.61M 968K Sep/2025
Baxter International USD 9.78B 68M Dec/2025
Bayer EUR 36.45B 2.93B Dec/2025
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
Biogen USD 6.56B 275.1M Mar/2026
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Emergent BioSolutions USD 903.2M 495.2M Jun/2023
Esperion Therapeutics USD 262.92M 1.76M Sep/2024
Gilead Sciences USD 24.94B 5M Dec/2025
GlaxoSmithKline GBP 19.06B 1.34B Mar/2026
Halozyme Therapeutics USD 2.14B 631.87M Dec/2025
Insmed USD 727.62M 275K Mar/2026
Ionis Pharmaceuticals USD 2.34B 9.5M Mar/2026
J&J USD 47.93B 2.14B Dec/2025
Lexicon Pharmaceuticals USD 99.51M 243K Dec/2023
Moderna USD 1.31B 571M Dec/2025
Omeros USD 442.16M 199K Sep/2023
Pfizer USD 63.73B 231M Mar/2026
PTC Therapeutics USD 286.94M 2.42B Mar/2026
Regeneron Pharmaceuticals USD 2.71B 300K Mar/2026
Sangamo BioSciences USD 0 0 Jun/2022
Sarepta Therapeutics USD 1.04B 210.44M Dec/2025
Teva Pharmaceutical Industries USD 17.09B 21M Dec/2025
United Therapeutics USD 200M 100M Mar/2025
Vertex Pharmaceuticals USD 1.99B 44M Mar/2026